Wednesday, September 16, 2015 | 8:00 AM - 2:15 PM
Award Winner Bert Vogelstein (Johns Hopkins School of Medicine; Howard Hughes Medical Institute)
This symposium will honor Dr. Bert Vogelstein, the recipient of the 2015 Dr. Paul Janssen Award for Biomedical Research, in recognition of his role in characterizing the underlying mechanisms of cancer. Symposium registration is free. Advance registration is required.
Friday, September 18, 2015 | 8:30 AM - 4:30 PM
Speakers: George S. Bloom (University of Virginia), Peter Davies (Feinstein Institute for Medical Research), Marc I. Diamond (University of Texas Southwestern Medical Center), Michael Hutton (Eli Lilly and Company), Khalid Iqbal (New York State Institute for Basic Research in Developmental Disabilities), Hartmuth C. Kolb (Johnson & Johnson, Janssen R&D), Nicole Leclerc (Université de Montréal), Kun Ping Lu (Harvard Medical School), Richard M. Ransohoff (Biogen)
Speakers at this symposium will address novel tau-centered mechanisms of neurodegeneration and new therapeutic approaches for many devastating neurological disorders.
Tuesday, September 29, 2015 | 12:00 PM - 5:00 PM
Speakers: Samie R. Jaffrey (Weill Cornell Medical College), Amy E. Palmer (University of Colorado)
This symposium features state of the art chemical tools and imaging strategies for metal ions, redox signaling species, and metabolites in the cell, cellular delivery and targeting approaches, and their application to studying life processes.
Thursday, October 15, 2015 | 8:00 AM - 5:00 PM
Speakers: Jonathan Braun (University of CaliforniaLos Angeles), Rudolph Clerval (Enterome), David N. Cook (Seres Health), Stanislav Dusko Ehrlich (King's College London), Michael A. Fischbach (University of California, San Francisco), Andrew Goodman (Yale School of Medicine), Sarkis Mazmanian (California Institute of Technology), Paul O'Toole (University College Cork), R. Balfour Sartor (University of North Carolina School of Medicine)
In the human colon, the microbiome forms one of the densest bacterial ecosystems known in nature. This symposium will highlight recent research innovations and therapeutic applications from the microbiome with a focus on gut health.
Tuesday, October 27, 2015 | 8:00 AM - 5:00 PM
Speakers: Andras J. Bauer (Boehringer Ingelheim USA), Alex Huang (Genentech), Michael Jackson (Sanford-Burnham Medical Research Institute), Bryan Laffitte (Genomics Institute of the Novartis Research Foundation), Jonathan A. Lee (Eli Lilly), Lorenz Mayr (AstraZeneca), Friedrich Metzger (F. Hoffmann-La Roche Ltd), Bruce A. Posner (University of Texas, Southwestern Medical Center), Aravind Subramanian (Broad Institute), Giulio Superti-Furga (Austrian Academy of Sciences), Sue Swalley (Novartis Institutes for Biomedical Research)
This symposium aims to deepen our understanding of phenotypic drug discovery and to foster the exchange of ideas between industry-based and academic research scientists.
Tuesday, July 28, 2015 | 8:30 AM - 6:00 PM
Speakers: Marc D Chioda (Pfizer Inc), Leonard James (Pfizer Inc), Iya Khalil (GNS Healthcare), Michael Matheny (Vanderbilt University), Jason H. Moore (University of Pennsylvania), Nicholas Tatonetti (Columbia University Medical Center), Craig P. Webb (NuMedii, Inc), Chunhua Weng (Columbia University), Diane Wuest (GNS Healthcare)
In the era of precision medicine, analyses of large volumes of data are key to developing targeted and effective therapeutics. This symposium explores how big data and predictive knowledge are used to guide drug development and clinical trials.
Thursday, June 11, 2015 | 8:45 AM - 5:15 PM
Keynote Speaker: Jane A. Driver (Brigham and Women's Hospital)
Speakers: Kurt Brunden (University of Pennsylvania), Stuart Calderwood (Harvard Medical School), Gary Landreth (Case Western Reserve University), Tamara Maes, PhD (Oryzon Genomics S.A.), David M. Roy (Memorial Sloan Kettering Cancer Center), Stephen Strittmatter (Yale University School of Medicine), Li Huei Tsai (Massachusetts Institute of Technology), Raymond Scott Turner (Georgetown University), Claes Wahlestedt (University of Miami Miller School of Medicine), Hui Zheng (Baylor College of Medicine)
Does having cancer decrease your risk of developing neurodegenerative diseases? Why do many cancer drug targets overlap with targets for neurodegenerative diseases? This meeting will address these questions to help advance therapeutic development.
Thursday, May 28, 2015 | 8:00 AM - 3:00 PM
Keynote Speaker: Craig B. Thompson (Memorial Sloan-Kettering Cancer Center)
Speakers: John Blenis (Weill Cornell Medical College ), Selina Chen-Kiang (Weill Cornell Medical College), Lydia Finley (Memorial Sloan-Kettering Cancer Center), Alec Kimmelman (Harvard Medical School), Christian Metallo (University of California, San Diego ), Elena Piskounova (University of Texas Southwestern Medical Center ), Sohail Tavazoie (The Rockefeller University), Matthew G. Vander Heiden (Massachusetts Institute of Technology)
This symposium will highlight insights into tumor metabolism from leaders in the field and explore how this information is being used to design safe and effective, metabolism-targeted therapies.
Tuesday, May 26, 2015 | 8:30 AM - 4:30 PM
Speakers: Richard Allen (Pfizer, Inc.), John Burke (Applied BioMath), Nitin Mehrotra (US Food and Drug Administration), Sian Ratcliffe (Pfizer Inc), Matthew Rizk (Merck & Co, Inc), Tim Rolph (Pfizer, Inc.), Vikram Sinha (US Food and Drug Administration), Peter Sorger (Harvard Medical School), Paul Watkins (Hamner-UNC Institute for Drug Safety Sciences)
Quantitative Systems Pharmacology (QSP) has been used successfully in drug discovery and development, yet lacks industry-wide adoption. This symposium highlights past successes and future challenges of using QSP in preclinical and clinical research.
Organizers: Lydia Finley (Memorial Sloan-Kettering Cancer Center), Steven S. Gross (Weill Cornell Medical College), Costas A. Lyssiotis (Weill Cornell Medical College), and Sonya Dougal (The New York Academy of Sciences)
Keynote Speaker: Craig B. Thompson (Memorial Sloan-Kettering Cancer Center)
There is resurgent interest in cancer cell metabolism as researchers seek to understand how metabolic pathways are altered in cancer and how these alterations can be exploited for therapeutic gain. This eBriefing discusses advances in the field.
Organizers: Nathalie Breysse (Lundbeck Research USA), Elena Dale (Lundbeck Research USA), and Sonya Dougal (The New York Academy of Sciences)
Non-motor symptoms are common but often overlooked in Parkinson's disease. This eBriefing examines new approaches to studying disease mechanisms, which could lead to a better understanding of pathogenesis and to the development of new therapies.
Edited by Claudio Carini
Discusses the development of biomarker-based companion diagnostics to optimize diagnosis and treatment choices.
Edited by Matthew E. Fink
(Weill Cornell Medical College), Jack D. Barchas
(Weill Cornell Medical College), and Javaid I. Sheikh
(Weill Cornell Medical College in Qatar)
Discussions of the latest translational research, advanced brain imaging, & novel diagnostics
A recent conference held at the Academy asked a downright outrageous question: Can dementia be prevented by making changes to your diet? In this podcast we look at what the answers might be.
In the second of a two-part series, experts look at the links between health and nutrition. They examine everything from how nutrition impacts hospital stays, to cancer and aging, to developing food science innovations, and improving diet.
In this first of a two-part series, experts from various sectors explore the available options to reduce "hidden hunger"—micronutrient deficiencies in a population.
February 23, 2010
Researchers met to discuss advances in basic and translational research on metabotropic glutamate receptors, which are promising targets in drug discovery for CNS diseases and other illnesses.
October 27, 2009
What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.
April 28, 2009
Protein kinases play a key role in almost every major pathway in eukaryotic cells. Structural approaches, including a new method called fragment-based drug design, are identifying potential targets against diseases including cancer.